Advertisement

Congestive Heart Failure

Proceedings of the Symposium on New Drugs and Devices October 30–31, 1986, Philadelphia, Pennsylvania

  • Joel Morganroth
  • E. Neil Moore

Part of the Developments in Cardiovascular Medicine book series (DICM, volume 75)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Epidemiology, Therapeutic Endpoints

  3. Preclinical Issues and Proarrhythmia Definitions

    1. Front Matter
      Pages 69-69
    2. Stewart J. Ehrreich
      Pages 71-96
    3. C. William Balke, Joseph F. Spear, E. Neil Moore
      Pages 97-103
    4. J. Morganroth
      Pages 105-115
    5. Back Matter
      Pages 131-140
  4. FDA Endpoint Issues

  5. Therapeutic Strategies

    1. Front Matter
      Pages 175-175
    2. Jay N. Cohn
      Pages 187-192
    3. Thierry H. Le Jemtel, Stuart Katz, Gad Keren, Edmund H. Sonnenblick
      Pages 193-209
    4. Back Matter
      Pages 233-248
  6. Clinical Trial Issues

  7. Back Matter
    Pages 279-290

About this book

Introduction

About 2. 5 million individuals have congestive heart fai lure in the United States with over 400,000 new cases expected annually. Congestive heart failure also is one of the commonest causes for hospital admissions accounting for over 5 million hospital days per year. Despite the early recognition of this condition and active medical research into both mechanisms and therapy, prognosis continues to remain dismal wi th less than a 50% expected five year survival. In the last decade we have seen many new medical and therapeutic options for patients with congestive heart failure which extend beyond the use of bed rest, sodium restriction, digitalis and diuretics. These include vasodilators of a variety of types including the angiotensin conventional enzyme (ACE) inhibitors. Also, many new inotropes are under active investigation both in oral and intravenous forms. In March of 1984 a survey of over 5000 physicians was performed under the auspices of the American Heart Association (reported in: JAOC 8:966, 1986). That survey showed that there was no universally accepted defini tion for congestive heart fai lure and that a wide spectrum of diagnostic cri teria for this common condi tion existed even among academic cardiologists. There was no clear standard as to even the mos t bas ic treatment of conges t i ve heart fai lure. For example, exercise restriction was recommended by 19% of physicians, 31% recommended no change in activity, and 50% either light exercise or an exercise conditioning program.

Keywords

arrhythmia drugs electrophysiology heart heart failure physiology sudden cardiac death

Editors and affiliations

  • Joel Morganroth
    • 1
  • E. Neil Moore
    • 2
  1. 1.Likoff Cardiovascular InstituteHahnemann UniversityPhiladelphiaUSA
  2. 2.School of Veterinary MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4613-2077-7
  • Copyright Information Springer-Verlag US 1987
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4612-9232-6
  • Online ISBN 978-1-4613-2077-7
  • Series Print ISSN 0166-9842
  • Buy this book on publisher's site